Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Clinical trial NCT00614393 · COMPLETED

Trial details

NCT number: NCT00614393
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Cancer

Start date: 2007-12-24
Primary completion: 2010-06-01
Enrollment: 558

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.